

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Item 8.01 Other Events.

On July 30, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that the European Patent Office has issued a key patent covering enteric-coated oral formulations of cysteamine bitartrate, including the Company's proprietary microbead formulation, RP103. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit		Filed
No.	Exhibit Description	Here Incorporated by Reference
		with Form File No. Exhibit Filing Date Filed By
99.1	Press release issued by the Company dated as of July 30, 2012	X

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: July 31, 2012 By: /s/ Kim R. Tsuchimoto
Name: Kim R. Tsuchimoto
Title: Chief Financial Officer, Treasurer and Secretary

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Exhibit Index

Exhibit	No.	Exhibit Description	Filed Here Incorporated by Reference with Form File No. Exhibit Filing Date Filed By
	99.1	Press release issued by the Company dated as of July 30, 2012	X